

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application.

1-17. (Cancelled)

18. (Currently amended) A method for controlled release of therapeutic, prophylactic, or diagnostic agents comprising administering to tissue in need thereof a biocompatible, polymerizable, macromer composition comprising at least one NO carrying region or NO modulating compound, wherein NO or the NO modulating compound is complexed to the macromer composition, and wherein the NO or the NO modulating compound is released from the macromer composition following polymerization *in situ*, under physiological conditions, wherein the ~~macromers comprise~~ macromer composition comprises regions selected from the group consisting of water soluble regions, tissue adhesive regions, and polymerizable end group regions and therapeutic, prophylactic or diagnostic agents selected from the group consisting of proteins, carbohydrates, nucleic acids, organic molecules, inorganic molecules, biologically active molecules, cells, tissue, tissue aggregates, and diagnostic agents.

19. (Cancelled)

20. (Currently amended) A method of treating a disorder or condition with NO comprising administering to an individual in need thereof a biocompatible, polymerizable, macromer composition comprising at least one NO carrying region or NO modulating compound, wherein NO or the NO modulating compound is complexed to the macromer composition, and wherein the NO or the NO modulating compound is released from the macromer composition following polymerization *in situ*, under physiological conditions, wherein the ~~macromers comprise~~ macromer composition comprises regions selected from the group consisting of water soluble regions, tissue adhesive regions, and polymerizable end group regions.

21. (Previously presented) The method of claim 20 wherein the macromer further comprises degradable regions.

22. (Previously presented) The method of claim 20 for treatment of a disorder or condition selected from the group consisting of wound healing, restenosis, thrombosis, asthma, arthritis, and erectile dysfunction.

23. (Previously presented) The method of claim 20 wherein the macromer is adhered to tissue to prevent surgical adhesions, adhere tissue, provide support for tissue or coat the tissue.

24. (Previously presented) The method of claim 22 wherein restenosis occurs after stint deployment.

25-31. (Cancelled)